A

ANAVEON AG

31 employees

Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions.

Basic info

Industry

biotechnology research

Sectors

Therapeutics
immunotherapy
cytokines
oncology

Date founded

2017

Funding rounds raised

Total raised

$119M

from 4 investors over 4 rounds

A

ANAVEON AG raised $119M on December 16, 2021

Investors: Syncona Limited, Forbion and Pontifax Venture Capital

A

ANAVEON AG raised $35M on February 26, 2019

Investors: Syncona Limited

FAQ